The most common inherited dyslipidemia, familial combined hyperlipidemia (FCHL), is associated with insulin resistance. Whether insulin sensitivity in these families is inherited is not known. Therefore, we investigated the inheritance of insulin sensitivity in 352 nondiabetic family members from 37 families with FCHL, 105 of whom had undergone testing using the hyperinsulinemic-euglycemic clamp technique for the measurement of insulin sensitivity. First, complex segregation analysis of fasting insulin levels (both unadjusted and age-, age2-, and BMI-adjusted) was used for modeling of the variance in fasting insulin levels. In these analyses, Mendelian codominant inheritance (P = 0.320 for unadjusted and P = 0.295 for adjusted insulin values) was not rejected over the most general model and fit the data significantly better than the sporadic model (P < 0.001). Polygenic and environmental models were rejected (P < 0.001). The Mendelian codominant model explained 44 and 45% of the variance in unadjusted and adjusted fasting insulin levels, respectively. The proposed genotypes of this locus, based on segregation analysis, were associated with directly measured insulin sensitivity in 105 FCHL family members who underwent the hyperinsulinemic-euglycemic clamp (P < 0.001). These results provide evidence for a major gene regulating insulin sensitivity in FCHL families. Possible pleiotropic effects of this insulin sensitivity locus on dyslipidemias in FCHL remain to be elucidated.

Familial combined hyperlipidemia (FCHL) is the most common familial dyslipidemia and is associated with increased risk of cardiovascular diseases (1). The prevalence in Western populations is reported to be ∼1%, but in patients who have coronary heart disease at young age, the prevalence may be as high as 20% (2,3). FCHL is characterized by different types of dyslipidemias (2,3) and insulin resistance (4,5,6,7,8). Most likely, FCHL is an oligogenic disorder (8,9). Major genes for triglycerides (2,10), apolipoprotein B (apoB) (11,12,13), and small, dense LDL (14,15) have been proposed, but so far no major genes for these traits have been mapped. However, several loci identified in genome-wide random searches have been proposed to modify lipid levels (16,17,18).

Insulin resistance, defined as insulin’s impaired ability to exert its normal function (19), can be quantified directly with the hyperinsulinemic-euglycemic clamp (20). In Pima Indians, insulin sensitivity measured by this technique has been reported to be distributed as a mixture of three normal distributions. This suggests that a major codominant gene may determine insulin sensitivity (21). Because the clamp study is difficult to perform in large families with several generations, fasting insulin level has been used as a surrogate of insulin action (22). Using segregation analysis in families randomly ascertained (23) or through siblings with type 2 diabetes (24), major genes have been proposed to determine fasting and postglucose insulin levels. These segregation analyses suggested a presence of a common allelic variation explaining ∼30% of the variance in insulin levels.

The inheritance of insulin levels or insulin resistance has not been studied previously in FCHL families. Therefore, we investigated the inheritance of fasting insulin levels in 37 FCHL kindreds with 352 nondiabetic family members using complex segregation analysis. Furthermore, we investigated whether the proposed fasting insulin locus determines insulin sensitivity in 105 FCHL family members who underwent the hyperinsulinemic-euglycemic clamp.

All participants in this study were Finnish. The Finnish population is genetically relatively homogeneous, originating mainly from southern (European) and eastern (Asian) immigration 2,000 years ago (25,26).

FCHL family members.

Twenty-five of the probands with FCHL were selected from the myocardial infarction survivor family study carried out at our department (27). Selection of the probands and criteria for FCHL have been described previously in detail (7). Briefly, cutoff points for lipids were 7.7 mmol/l for total cholesterol in both men and women and 2.2 mmol/l for total triglycerides in women and 2.4 mmol/l in men. These cutoff points were based on the lipid values of the control population, which consisted of 250 people (161 males and 89 females) of the same myocardial infarction survivor family study from which FCHL families were identified. The cutoff points for abnormal lipids were defined as 80th percentile for total cholesterol and 90th percentile for total triglycerides. The 80th percentile for total cholesterol was used because of high cholesterol level among participants living in eastern Finland. After adjustment for age with linear regression analysis, the values for the median age (55 years) of this population were used as cutoff points for abnormal lipids. To meet the criteria for FCHL, each family had to have at least three affected members with different types of dyslipidemias and at least one affected family member in two different generations. Combined hyperlipidemia had to be present in the family but not necessarily in the proband. In addition, 12 FCHL probands and their families were identified from the Coronary Angiography Register of the Kuopio University Hospital according to the previously mentioned lipid criteria. None of the study participants had tendon xanthomas or defects in the LDL receptor gene, which explain ∼90% of all cases of familial hypercholesterolemia in this area (28). Nineteen participants with type 2 diabetes according to the World Health Organization criteria (29) and three participants with very high fasting insulin values over 300 pmol/l were excluded from the study to avoid extreme skewness of the insulin distribution. Altogether, 37 families with FCHL and their 352 family members (37 probands, 82 siblings of the probands, 46 children of the probands, 128 second-degree relatives, and 58 spouses) met the criteria and were included in this study (Table 1). All included FCHL family members had a normal glucose tolerance; normal liver, kidney, and thyroid function tests; no history of excessive alcohol intake; and no severe chronic disease.

Subset of FCHL family members for metabolic studies.

All family members with dyslipidemia and a random sample of relatives without dyslipidemia were invited for the hyperinsulinemic-euglycemic clamp, after exclusion of participants who were ≤30 years of age and those with severe chronic disease (8,9). This resulted in a sample of 105 family members, including 50 relatives without dyslipidemia (29 men, 21 women), 19 with hypercholesterolemia (14 men, 5 women), 22 with hypertriglyceridemia (16 men, 6 women), and 14 with combined hyperlipidemia (8 men, 6 women).

Informed consent was obtained from all participants after the purpose and potential risks of the study were explained to them. The protocol was approved by the Ethics Committee of the University of Kuopio and was in accordance with the Helsinki Declaration.

Determination of insulin sensitivity.

The degree of insulin sensitivity was evaluated with the hyperinsulinemic-euglycemic clamp technique (20). After baseline blood drawing, a priming dose of insulin (Actrapid 100 IU/ml; Novo Nordisk, Gentofte, Denmark) was administered during the initial 10 min to raise plasma insulin concentration quickly to the desired level, where it was maintained by a continuous insulin infusion of 480 pmol/m2 per min. Under these study conditions, hepatic glucose production is completely suppressed in nondiabetic participants (30) and in FCHL patients (4). Blood glucose was clamped at 5.0 mmol/l for the next 180 min by the infusion of 20% glucose at varying rates according to blood glucose measurements performed at 5-min intervals. The mean rates of glucose infusion during the last hour of the clamp were used to calculate the rates of insulin-stimulated whole-body glucose uptake (WBGU).

Analytical methods.

Plasma glucose levels in the fasting state and after an oral glucose load as well as blood glucose levels during the euglycemic clamp were measured by the glucose oxidase method (2300 Stat Plus; Yellow Springs Instrument, Yellow Springs, OH). For the determination of plasma insulin, blood was collected in EDTA-containing tubes, and after centrifugation the plasma was stored at −20°C until the analysis. Plasma insulin concentration was determined by a commercial double-antibody solid-phase radioimmunoassay (Phadeseph Insulin RIA 100; Pharmacia Diagnostics AB, Uppsala, Sweden). Cholesterol and triglyceride levels from whole serum and lipoprotein fractions were assayed by automated enzymatic methods (Boehringer-Mannheim, Mannheim, Germany). ApoB levels were determined by a commercial immunoturbidimetric method (Kone Instruments, Espoo, Finland).

Statistical analysis.

All basic calculations were done with the SPSS/Win programs (version 7.5; SPSS, Chicago). Because of the skewed distribution of insulin levels, they were logarithmically transformed to achieve a distribution not significantly different from normal (for log-transformed fasting insulin, P = 0.196, Kolmogorov-Smirnov test) before statistical analysis. Bivariate Pearson correlations were calculated between log-transformed fasting and 2-h postglucose insulin values and the rates of WBGU. Fasting insulin had a stronger negative correlation (r = −0.617) with the rates of WBGU than 2-h postglucose insulin (r = −0.485) and therefore was used in segregation analysis.

Segregation analysis of fasting insulin levels.

To investigate the genetic and environmental influences on fasting insulin levels in the FCHL families, we evaluated a series of class D regressive models using the REGC program (S.A.G.E., version 2.2, Cleveland, OH) (31). These models assume that the variation among individuals for a quantitative trait is the result of a major gene effect and a residual variation caused by both additional familial correlations and individual variance. Additional familial correlations may reflect both polygenic effects and unmeasured common environmental effects. Based on a maximum likelihood method in the most general model, all parameters are estimated. Eleven parameters are considered. First, the frequency of a single factor assuming two alleles A and B (i.e., an allelic variation in a major gene) following Hardy-Weinberg equilibrium was estimated. The mean insulin value associated with each of the possible three genotypes μAA, μAB, and μBB was estimated assuming equal variance ς2 among all genotypes. In the most general model, Mendelian inheritance was not assumed and the probabilities of transmission τAA, τAB, and τBB also were estimated. Finally, the correlation of the remaining variance between spouse, parent-offspring, and sib-sib pairs was calculated.

Thereafter, seven restricted models were compared with the general model. First, a model assuming a Mendelian inheritance in which transmission probabilities were fixed to 1, 0.5, and 0 was considered (eight parameters estimated). Second, a polygenic model in which familial correlation was allowed but μAA = μAB = μBB were fixed and therefore no genotype-effect was allowed (five parameters estimated). Third, an environmental model in which transmission was fixed similar in all genotypes indicating a nongenetic effect (nine parameters estimated). Fourth, the model was a sporadic model in which no type-effect, transmission, and additional correlation were allowed (two parameters estimated). Fifth, in the pure codominant model, the Mendelian model was restricted further by fixing additional familial correlations to 0 (five parameters estimated). Finally, two submodels of codominant model in which either recessive (μAA = μAB) or dominant (μAB = μBB) were considered (four parameters estimated). In the second segregation analysis, the effect of age, age2, BMI, and sex also was included in the model. Restricted models were compared with the most general model by using the likelihood ratio test in which the difference in −2ln(Likelihood) of the submodels follows χ2 distribution with degree of freedom equal to difference in the number of estimated parameters in each model. No correction for ascertainment was used. Family trees are available on request to interested readers (contact J.P.).

The effect of the fasting insulin locus on insulin resistance was investigated by comparing insulin sensitivity in participants with assigned genotypes AA, AB, and BB for the proposed fasting insulin locus identified by segregation analysis. Genotype was assigned when the likelihood of a genotype was higher than 0.6 in a given family member. When no genotype had a likelihood higher than 0.6, that family member was excluded from this portion of the analysis. Then, mean values of insulin-stimulated rates of WBGU were compared in 105 available family members according to this assigned genotype using analysis of variance with contrasts to estimate the effect of individual genotypes.

Characteristics of the FCHL probands and family members.

Characteristics of 37 FCHL probands and all 352 FCHL family members, including the probands and subset of FCHL family members who underwent metabolic studies, are shown in Table 1.

Segregation analysis of fasting insulin levels.

In univariate segregation analysis based on unadjusted fasting insulin levels (after logarithmic transformation), the Mendelian codominant inheritance model (model 2) could not be rejected over the most general model (model 1, P = 0.320), whereas pure polygenic, environmental, and sporadic models were rejected (models 3, 4, and 5, all P < 0.001; Table 2). The Mendelian codominant inheritance model with additional familial correlation did not differ from models with dominant or recessive inheritance (P = 0.087, models not shown). The Mendelian codominant model with familial correlation restricted to 0 also was accepted (model 6, P = 0.105). However, restriction of Mendelian model to either dominant or recessive inheritance (models 7 and 8) led to the rejection of these models (P = 0.035). Thus, Mendelian codominant model provided the best fit to the family data and suggested a major gene effect on fasting insulin levels with a B allele frequency of 0.26 (associated with higher insulin levels) and genotypic means of insulin 47.5 for the genotype AA, 71.0 for AB, and 155.4 pmol/l for BB. The difference in the variance of insulin levels explained by the Mendelian and sporadic model was 0.245 − 0.135 = 0.110, suggesting that 44% (0.110/0.245) of the variance in fasting insulin was explained by this locus. These values corresponded well with the observed distribution of fasting insulin levels in these families (Fig. 1).

Inclusion of covariates (age, age2, and BMI) into the segregation models improved the fit of all models with the data (P < 0.001) but did not change the main results of analysis (Table 2). In all models, the regression coefficients were similar: 0.0004 for age2, −0.037 for age, and 0.061 for BMI. Sex-dependent models did not fit the data better than respective sex-independent models (data not shown). Similar to the analysis of unadjusted insulin values, Mendelian codominant model could not be rejected (model 2, P = 0.295) and the pure codominant model without additional familial correlations (model 6, P = 0.412) was the best-fitting model. Also in this analysis, polygenic, environmental, sporadic models (models 3–5) and dominant (model 7) and recessive (model 8) submodels of the codominant model were rejected (all P < 0.001). The segregation analysis of adjusted insulin levels suggested a major gene effect on fasting insulin levels with the B allele frequency of 0.22 and adjusted (to mean age and BMI shown in Table 1) genotypic means of insulin 52.0 for the genotype AA, 76.2 for AB, and 132.3 pmol/l for BB. In this case, the difference in residual variance between Mendelian and the sporadic models was 0.141 − 0.077 = 0.064, suggesting that 45% (0.064/0.141) of the variance in fasting insulin was explained by this locus, compared with 44% shown above based on the segregation analysis of unadjusted insulin values.

The effect of proposed insulin locus on insulin resistance.

To investigate the effect of the proposed insulin locus on insulin resistance, we calculated the likelihoods of the genotypes AA, AB, and BB for each individual who underwent the hyperinsulinemic clamp for the estimation of insulin sensitivity. When genotypes based on the segregation analysis of unadjusted insulin values were used, 90 of the 105 family members had genotype probabilities of 0.6 or higher. Of these, 48 had genotype AA, 36 had genotype AB, and six had genotype BB. The rates of WBGU differed among participants with these assigned genotypes (P < 0.001, analysis of variance over the three genotypes; Fig. 2). Both participants with the AB genotype (P = 0.015) and participants with the BB genotype (P = 0.032) had lower rates of WBGU than participants with the AA genotype. Similarly, when 85 participants were assigned genotype on the basis of the segregation analysis, including covariates, participants with the genotype AA had higher rates of WBGU than participants with the genotype AB (n = 66 and n = 19; P = 0.010; Fig. 2).

In FCHL, earlier studies indicated the presence of major genes for triglycerides (2,10), apoB (11,12,13), and small, dense LDL (14,15), suggesting an oligenic background for this disease. This study demonstrates that fasting insulin levels also are determined by a major gene locus in these families. Because this proposed locus also was associated with directly measured insulin sensitivity in these families, we infer that insulin sensitivity, which is an essential characteristic of FCHL (4,5,6,7,8), also is at least partly genetically determined in these families.

Impaired insulin action, i.e., insulin resistance, has been acknowledged as a central part of the metabolic syndrome, which is an important risk factor for cardiovascular diseases (19,32). Because patients with FCHL have several components of the metabolic syndrome, e.g., hypertriglyceridemia (2,3), postprandial lipemia (33), high prevalence of small, dense LDL particles (14,34,35), low HDL cholesterol levels (36,37), and central obesity (38), it is not surprising that these patients also have hyperinsulinemia (33,37) as a result of insulin resistance (4,5,6). Our earlier studies suggested that insulin resistance also is present in young relatives of FCHL patients who are at risk to develop FCHL. Therefore, we hypothesized that a gene defect in insulin action may be important in FCHL (7).

The segregation analysis of fasting insulin levels in this study suggests that a major gene may explain up to 40% of the variance in fasting insulin levels in nondiabetic members of FCHL families. This may be an upper estimate because families were ascertained via dyslipidemic (hyperinsulinemic) family members. However, the finding is not surprising because similar results have been obtained in nondiabetic members of families with or without type 2 diabetes (23,24). In all of these studies, diabetic patients have been excluded because in diabetic patients, a major genetic effect on insulin levels is likely to be overruled by the insulin-elevating effect of various glucose levels. We used fasting insulin level as a surrogate for directly measured insulin sensitivity because direct measurement of insulin sensitivity is not feasible in families with several generations. We are confident that our results suggest that also insulin sensitivity is inherited in FCHL families for two reasons. First, fasting insulin has a correlation of −0.60 to −0.70 with directly measured insulin sensitivity (22), which was also the case in this study. Second, the proposed genotypes of the assumed fasting insulin locus were associated with directly measured insulin sensitivity.

Only a few genes that determine insulin sensitivity in humans are known. Uncommon mutations in the insulin gene and in the insulin receptor gene can cause insulin resistance (39) and mutations in the peroxisome proliferator–activated receptor-γ gene are known to impair insulin sensitivity (40,41,42). However, our previous results show that the peroxisome proliferator–activated receptor-γ variants are not the cause of insulin resistance in Finnish FCHL families (43). We also have excluded many other genes as major determinants of insulin sensitivity in FCHL, e.g., the genes encoding fatty acid binding protein 2 (44), β3-adrenergic receptor and uncoupling protein 1 (45), angiotensinogen-converting enzyme, and apolipoprotein E (unpublished findings). The hepatic lipase gene recently was proposed to play a role in FCHL (46,47), and we have suggested that the promoter variants in that gene also may regulate insulin sensitivity in FCHL families (48). However, the estimates of the impact of these genes may be biased because the currently unknown major genes in FCHL families may have a confounding effect on the results. Therefore, the search for major genes in FCHL is essential.

Because of the known association between high serum triglycerides and insulin resistance both in the general population (49) and in FCHL families (6,8), the novel loci that have been linked to FCHL (17,18), especially with serum triglycerides in FCHL families (50,51), also are promising with respect to insulin resistance. In fact, genes may have a pleiotropic effect on several lipoprotein traits and insulin sensitivity, and therefore the search for novel FCHL genes may be more effective if combined phenotypes are used (52).

FIG. 1.

Distribution of unadjusted fasting insulin levels in 352 FCHL family members. Vertical lines indicate mean values for genotypes AA, AB, and BB based on segregation analysis.

FIG. 1.

Distribution of unadjusted fasting insulin levels in 352 FCHL family members. Vertical lines indicate mean values for genotypes AA, AB, and BB based on segregation analysis.

FIG. 2.

Insulin-stimulated WBGU in participants with assigned genotypes AA, AB, and BB of the insulin resistance locus proposed by the segregation analysis of unadjusted fasting insulin levels (A) and by segregation analysis with covariates (age, age2, and BMI) (B). Means are shown as horizontal lines (analysis of variance over the three genotypes).

FIG. 2.

Insulin-stimulated WBGU in participants with assigned genotypes AA, AB, and BB of the insulin resistance locus proposed by the segregation analysis of unadjusted fasting insulin levels (A) and by segregation analysis with covariates (age, age2, and BMI) (B). Means are shown as horizontal lines (analysis of variance over the three genotypes).

TABLE 1

Characteristics of study groups

ProbandsAll relatives*Subset of relatives
n 37 352 105 
Sex (M/F) 25/12 171/181 65/40 
Age (years) 60.4 ± 8.5 47.8 ± 16.0 50.5 ± 11.5 
BMI (kg/m228.4 ± 4.6 26.8 ± 5.2 27.1 ± 5.0 
Waist-to-hip ratio 0.94 ± 0.08 0.92 ± 0.10 0.94 ± 0.08 
Systolic blood pressure (mmHg) 138 ± 17 135 ± 18 134 ± 17 
Diastolic blood pressure (mmHg) 85 ± 10 81 ± 11 85 ± 11 
Fasting plasma glucose (mmol/l) 6.8 ± 3.0 5.5 ± 0.8 5.5 ± 0.5 
Fasting plasma insulin (pmol/l) 86.4 ± 45.0 69.6 ± 40.8 69.6 ± 37.8 
Total cholesterol (mmol/l) 7.48 ± 1.28 6.48 ± 1.37 6.89 ± 1.26 
HDL cholesterol (mmol/l) 1.23 ± 0.30 1.31 ± 0.30 1.29 ± 0.27 
Total triglycerides (mmol/l) 2.83 ± 1.62 1.87 ± 1.17 2.15 ± 1.19 
ApoB (g/l) 1.44 ± 0.36 1.15 ± 0.31 1.24 ± 0.31 
ProbandsAll relatives*Subset of relatives
n 37 352 105 
Sex (M/F) 25/12 171/181 65/40 
Age (years) 60.4 ± 8.5 47.8 ± 16.0 50.5 ± 11.5 
BMI (kg/m228.4 ± 4.6 26.8 ± 5.2 27.1 ± 5.0 
Waist-to-hip ratio 0.94 ± 0.08 0.92 ± 0.10 0.94 ± 0.08 
Systolic blood pressure (mmHg) 138 ± 17 135 ± 18 134 ± 17 
Diastolic blood pressure (mmHg) 85 ± 10 81 ± 11 85 ± 11 
Fasting plasma glucose (mmol/l) 6.8 ± 3.0 5.5 ± 0.8 5.5 ± 0.5 
Fasting plasma insulin (pmol/l) 86.4 ± 45.0 69.6 ± 40.8 69.6 ± 37.8 
Total cholesterol (mmol/l) 7.48 ± 1.28 6.48 ± 1.37 6.89 ± 1.26 
HDL cholesterol (mmol/l) 1.23 ± 0.30 1.31 ± 0.30 1.29 ± 0.27 
Total triglycerides (mmol/l) 2.83 ± 1.62 1.87 ± 1.17 2.15 ± 1.19 
ApoB (g/l) 1.44 ± 0.36 1.15 ± 0.31 1.24 ± 0.31 

Data are means ± SD.

*

Includes probands and a subset of relatives in metabolic studies;

includes a subset of relatives in metabolic studies.

TABLE 2

Segregation analysis of logarithmically transformed insulin values (backtransformed values shown) in Finnish FCHL families

PμAAμABμBBτAAτABτBBς2rsprporss−2Ln(L)χ2 (df)P value
Unadjusted fasting insulin (pmol/l)               
 General 0.73 45.6 82.5 184.3 0.95 0.65 0.42 0.098 0.35 −0.11 0.07 454.2 . . .  
 Mendelian 0.75 46.6 76.9 166.7 (1) (0.5) (0) 0.120 0.31 −0.14 0.06 457.7 3.5 (3) 0.320 
 Polygenic (1) 61.7 AA AA (1) (0.5) (0) 0.238 0.15 0.10 0.14 482.7 28.7 (6) <0.001 
 Environmental 0.71 61.1 51.5 188.0 =P =P =P 0.218 0.37 0.07 0.14 473.3 19.1 (2) <0.001 
 Sporadic (1) 61.1 AA AA (1) (0.5) (0) 0.245 (0) (0) (0) 502.6 48.4 (9) <0.001 
 Codominant 0.74 47.5 71.0 155.4 (1) (0.5) (0) 0.135 (0) (0) (0) 463.3 9.1 (6) 0.105 
 Dominant 0.38 122.1 54.1 AB (1) (0.5) (0) 0.158 (0) (0) (0) 469.3 15.1 (7) 0.035 
 Recessive 0.62 54.1 AA 122.1 (1) (0.5) (0) 0.158 (0) (0) (0) 469.3 15.1 (7) 0.035 
Fasting insulin (pmol/l) adjusted for age, age2, and BMI               
 General 0.87 41.7 60.4 99.9 0.88 0.46 [0] 0.078 0.46 0.05 0.21 254.2 . . .  
 Mendelian 0.78 52.5 73.9 128.4 (1) (0.5) (0) 0.084 0.46 0.02 0.11 257.9 3.7 (3) 0.295 
 Polygenic (1) 50.4 AA AA (1) (0.5) (0) 0.134 0.34 0.19 0.21 266.5 12.4 (6) <0.001 
 Environmental 0.93 47.8 191.8 156.9 =P =P =P 0.104 0.49 0.19 0.24 296.3 42.1 (6) <0.001 
 Sporadic (1) 54.7 AA AA (1) (0.5) (0) 0.141 (0) (0) (0) 308.1 52.9 (9) <0.001 
 Codominant 0.78 52.0 76.2 132.3 (1) (0.5) (0) 0.077 (0) (0) (0) 258.3 6.1 (6) 0.412 
 Dominant 0.17 80.1 49.4 AB (1) (0.5) (0) 0.088 (0) (0) (0) 274.4 20.9 (7) <0.001 
 Recessive 0.83 49.4 AA 80.1 (1) (0.5) (0) 0.091 (0) (0) (0) 274.4 20.9 (7) <0.001 
PμAAμABμBBτAAτABτBBς2rsprporss−2Ln(L)χ2 (df)P value
Unadjusted fasting insulin (pmol/l)               
 General 0.73 45.6 82.5 184.3 0.95 0.65 0.42 0.098 0.35 −0.11 0.07 454.2 . . .  
 Mendelian 0.75 46.6 76.9 166.7 (1) (0.5) (0) 0.120 0.31 −0.14 0.06 457.7 3.5 (3) 0.320 
 Polygenic (1) 61.7 AA AA (1) (0.5) (0) 0.238 0.15 0.10 0.14 482.7 28.7 (6) <0.001 
 Environmental 0.71 61.1 51.5 188.0 =P =P =P 0.218 0.37 0.07 0.14 473.3 19.1 (2) <0.001 
 Sporadic (1) 61.1 AA AA (1) (0.5) (0) 0.245 (0) (0) (0) 502.6 48.4 (9) <0.001 
 Codominant 0.74 47.5 71.0 155.4 (1) (0.5) (0) 0.135 (0) (0) (0) 463.3 9.1 (6) 0.105 
 Dominant 0.38 122.1 54.1 AB (1) (0.5) (0) 0.158 (0) (0) (0) 469.3 15.1 (7) 0.035 
 Recessive 0.62 54.1 AA 122.1 (1) (0.5) (0) 0.158 (0) (0) (0) 469.3 15.1 (7) 0.035 
Fasting insulin (pmol/l) adjusted for age, age2, and BMI               
 General 0.87 41.7 60.4 99.9 0.88 0.46 [0] 0.078 0.46 0.05 0.21 254.2 . . .  
 Mendelian 0.78 52.5 73.9 128.4 (1) (0.5) (0) 0.084 0.46 0.02 0.11 257.9 3.7 (3) 0.295 
 Polygenic (1) 50.4 AA AA (1) (0.5) (0) 0.134 0.34 0.19 0.21 266.5 12.4 (6) <0.001 
 Environmental 0.93 47.8 191.8 156.9 =P =P =P 0.104 0.49 0.19 0.24 296.3 42.1 (6) <0.001 
 Sporadic (1) 54.7 AA AA (1) (0.5) (0) 0.141 (0) (0) (0) 308.1 52.9 (9) <0.001 
 Codominant 0.78 52.0 76.2 132.3 (1) (0.5) (0) 0.077 (0) (0) (0) 258.3 6.1 (6) 0.412 
 Dominant 0.17 80.1 49.4 AB (1) (0.5) (0) 0.088 (0) (0) (0) 274.4 20.9 (7) <0.001 
 Recessive 0.83 49.4 AA 80.1 (1) (0.5) (0) 0.091 (0) (0) (0) 274.4 20.9 (7) <0.001 

P, frequency of the A allele; μAA, AB, BB, means for each ousiotype; τAA, AB, BB, transmission probabilities for each ousiotype; ς2, residual variance; rsp correlation between spouses; rpo, correlation between parents and offspring; rss, correlation between siblings; −2Ln(L), −2 times natural logarithm of the likelihood of each model; χ2, difference in −2Ln(L) compared with the general model (in parentheses is the difference in estimated parameters, which is equal to degree of freedom). Values fixed before analysis in each model are in parentheses.

This study was supported by grants from the Medical Research Council of the Academy of Finland and was performed during M.A.’s tenure as an Established Investigator of the American Heart Association. We thank Andy Louie for technical support.

The results of this paper were partly obtained with the S.A.G.E. Statistical Analysis for Genetic Epidemiology, Release 2.2. 1994 Computer program package available from the Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio. This program is supported by a U.S. Public Health Service Grant (1P41RR03655) from the National Center for Research Resources.

1.
Austin M, Mcknight B, Edwards K, Bradley C, McNeely M, Psaty B, Brunzell J, Motulsky A: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a twenty-year prospective study.
Circulation
101
:
2777
–2782,
2000
2.
Goldstein J, Schrott H, Hazzard W, Bierman E, Motulsky A: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.
J Clin Invest
52
:
1544
–1568,
1973
3.
Nikkilä E, Aro A: A family study of lipids and lipoproteins in coronary heart disease.
Lancet
1
:
954
–958,
1973
4.
Aitman T, Godsland I, Farren B, Crook D, Wong J, Scott J: Defects in insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia.
Arterioscler Thromb Vasc Biol
17
:
748
–754,
1997
5.
Bredie S, Cees J, Smits P, Stalenhoef A: Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives.
Arterioscler Thromb Vasc Biol
17
:
1465
–1471,
1997
6.
Ascaso J, Merchante A, Lorente R, Real J, Martinez-Valls J, Carmena R: A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients.
Metabolism
47
:
508
–513,
1998
7.
Karjalainen L, Pihlajamäki J, Karhapää P, Laakso M: Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia—a precursor defect for dyslipidemias?
Arterioscler Thromb Vasc Biol
18
:
1548
–1553,
1998
8.
Pihlajamäki J, Karjalainen L, Karhapää P, Vauhkonen I, Laakso M: Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia but insulin resistance is observed only in hypertriglyceridemic patients.
Arterioscler Thromb Vasc Biol
20
:
164
–170,
2000
9.
Kwiterovich P: Genetics and molecular biology of familial combined hyperlipidemia.
Curr Opin Lipidol
4
:
133
–143,
1993
10.
Cullen P, Farren B, Scott J, Farrall M: Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia.
Arterioscler Thromb
14
:
1233
–1249,
1994
11.
Jarvik GP, Beaty TH, Gallagher PR, Coates PM, Cortner JA: Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia.
Genet Epidemiol
10
:
257
–270,
1993
12.
Jarvik G, Brunzell J, Austin M, Krauss R, Motulsky A, Wijsman E: Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype.
Arterioscler Thromb
14
:
1687
–1694,
1994
13.
Bredie S, van Drongelen J, Kiemeney L, Demacker P, Beaty T, Stalenhoef A: Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.
Arterioscler Thromb Vasc Biol
17
:
834
–840,
1997
14.
Austin M, Brunzell J, Fitch W, Krauss R: Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia.
Arteriosclerosis
10
:
520
–530,
1990
15.
Bredie S, Kiemeney L, de Haan A, Demacker P, Stalenhoef A: Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.
Am J Hum Genet
58
:
812
–822,
1996
16.
Pajukanta P, Terwilliger J, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, Parkkonen M, Hartiala J, Ylitalo K, Pihlajamäki J, Porkka K, Laakso M, Viikari J, Ehnholm C, Taskinen M, Peltonen L: Genome-wide scan for familial combined hyperlipidemia genes in Finnish families suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B.
Am J Hum Genet
64
:
1453
–1463,
1999
17.
Aouizerat B, Allayee H, Cantor R, Davis R, Lanning C, Wen P, Dallinga-Thie G, de Bruin T, Rotter J, Lusis A: A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11.
Am J Hum Genet
65
:
397
–412,
1999
18.
Aouizerat BE, Allayee H, Cantor RM, Dallinga-Thie GM, Lanning CD, de Bruin TW, Lusis AJ, Rotter JI: Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16q.
Arterioscler Thromb Vasc Biol
19
:
2730
–2736,
1999
19.
Reaven G: Role of insulin resistance in human disease.
Diabetes
37
:
1595
–1607,
1988
20.
DeFronzo R, Tobin J, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and insulin resistance.
Am J Physiol
237: E214–E223,
1979
21.
Bogardus C, Lillioja S, Nyomba BL, Zurlo F, Swinburn B, Esposito-Del Puente A, Knowler WC, Ravussin E, Mott DM, Bennett PH: Distribution of in vivo insulin action in Pima Indians as mixture of three normal distributions.
Diabetes
38
:
1423
–1432,
1989
22.
Laakso M: How good a marker is insulin level for insulin resistance?
Am J Epidemiol
137
:
959
–965,
1993
23.
Mitchell BD, Kammerer CM, Hixson JE, Atwood LD, Hackleman S, Blangero J, Haffner SM, Stern MP, MacCluer JW: Evidence for a major gene affecting postchallenge insulin levels in Mexican-Americans.
Diabetes
44
:
284
–289,
1995
24.
Schumacher MC, Hasstedt SJ, Hunt SC, Williams RR, Elbein SC: Major gene effect for insulin levels in familial NIDDM pedigrees.
Diabetes
41
:
416
–423,
1992
25.
De la Chapelle A: Disease gene mapping in isolated human populations the example of Finland.
J Med Genet
30
:
857
–865,
1993
26.
Kittles R, Perola M, Peltonen L, Bergen A, Aragon R, Virkkunen M, Linnoila M, Goldman D, Long J: Dual origins of Finns revealed by Y chromosome haplotype variation.
Am J Hum Genet
62
:
1171
–1179,
1998
27.
Voutilainen E: Serum Lipids and Lipoproteins in Male Survivors of Acute Myocardial Infarction and Their First-Degree Relatives: A Case-Control Study. Kuopio, Finland, Kuopio University Publications,
1992
28.
Koivisto U, Hämäläinen L, Taskinen M, Kettunen K, Kontula K: Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction.
J Lipid Res
34
:
269
–277,
1993
29.
WHO:
Diabetes Mellitus: Report of a WHO Study Group.
Geneva, Switzerland, World Health Organization,
1985
30.
Bergman R, Finegood D, Ader M: Assessment of insulin sensitivity in vivo.
Endocrinol Rev
5
:
45
–86,
1985
31.
Bonney GE: On the statistical determination of major gene mechanisms in continuous human traits: regressive models.
Am J Med Genet
18
:
731
–749,
1984
32.
Reaven G: The role of insulin resistance and hyperinsulinemia in coronary heart disease.
Metab Clin Exp
41
:
16
–19,
1992
33.
Cabezas M, de Bruin T, Jansen H, Kock L, Kortlandt W, Erkelens D: Impaired chylomicron remnant clearance in familial combined hyperlipidemia.
Arterioscler Thromb
13
:
804
–814,
1993
34.
Hokanson J, Krauss R, Albers J, Austin M, Brunzell J: LDL physical and chemical properties in familial combined hyperlipidemia.
Arterioscler Thromb Vasc Biol
15
:
452
–459,
1995
35.
Ascaso J, Lorente R, Merchante A, Real J, Priego A, Carmena R: Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease.
Am J Cardiol
80
:
484
–487,
1997
36.
Brunzell J, Albers J, Chait A, Grundy S, Groszek E, McDonald G: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
J Lipid Res
24
:
147
–155,
1983
37.
Hunt S, Wu L, Hopkins P, Stults B, Kuida H, Ramirez M, Lalouel J, Williams R: Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.
Arteriosclerosis
9
:
335
–344,
1989
38.
Ascaso J, Sales J, Merchante A, Real J, Lorente R, Martinez-Valls J, Carmena R: Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidemia.
Int J Obes Relat Metab Disord
21
:
360
–366,
1997
39.
Taylor S: Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene.
Diabetes
41
:
1473
–1490,
1992
40.
Deeb S, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala: substitution in the human peroxisome proliferator activated receptor gamma 2 is associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
Nat Genet
20
:
284
–287,
1998
41.
Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn C: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.
N Engl J Med
339
:
953
–959,
1998
42.
Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O’Rahilly S: Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension.
Nature
402
:
880
–883,
1999
43.
Pihlajamäki J, Miettinen R, Valve R, Karjalainen L, Mykkänen L, Kuusisto J, Deeb S, Auwerx J, Laakso M: The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia.
Atherosclerosis
151
:
567
–574,
2000
44.
Pihlajamäki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M: Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia.
Arterioscler Thromb Vasc Biol
17
:
1039
–1044,
1997
45.
Pihlajamäki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M: Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia.
Metabolism
47
:
1397
–1402,
1998
46.
Gehrisch S, Kostka H, Tiebel M, Patzak A, Paetzold A, Julius U, Schroeder HE, Hanefeld M, Jaross W: Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia.
J Mol Med
77
:
728
–734,
1999
47.
Allayee H, Dominguez KM, Aouizerat BE, Krauss RM, Rotter JI, Lu J, Cantor RM, de Bruin TW, Lusis AJ: Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia.
J Lipid Res
41
:
245
–252,
2000
48.
Pihlajamäki J, Karjalainen L, Karhapää P, Vauhkonen I, Taskinen M, Deeb S, Laakso M: The G-250A substitution in the promoter of the hepatic lipase gene is associated with dyslipidemias and insulin resistance in healthy controls and in members of families with familial combined hyperlipidemia.
Arterioscler Thromb Vasc Biol
20
:
1789
–1795,
2000
49.
Laakso M: Dyslipidaemias, insulin resistance and atherosclerosis.
Ann Med
24
:
505
–509,
1992
50.
Pajukanta P, Nuotio I, Terwilliger J, Porkka K, Ylitalo K, Pihlajamäki J, Suomalainen A, Syvänen A, Lehtimäki T, Viikari J, Laakso M, Taskinen M, Ehnholm C, Peltonen L: Linkage of familial combined hyperlipidaemia to chromosome 1q21–q23.
Nat Genet
18
:
369
–373,
1998
51.
Pei W, Baron H, Muller-Myhsok B, Knoblauch H, Al-Yahyaee SA, Hui R, Wu X, Liu L, Busjahn A, Luft FC, Schuster H: Support for linkage of familial combined hyperlipidemia to chromosome 1q21–q23 in Chinese and German families.
Clin Genet
57
:
29
–34,
2000
52.
Edwards KL, Mahaney MC, Motulsky AG, Austin MA: Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families.
Arterioscler Thromb Vasc Biol
19: 2456–2464,
1999

Address correspondence and reprint requests to Jussi Pihlajamäki, MD, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail: pihlajam@uku.fi.

Received for publication 14 December 2000 and accepted in revised form 18 June 2001.

apoB, apolipoprotein B; FCHL, familial combined hyperlipidemia; WBGU, whole-body glucose uptake.